Nurix Therapeutics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −1.98%.
Did NRIX Beat Earnings? Q4 2025 Results
Nurix Therapeutics delivered a cleaner-than-expected Q4 fiscal 2025, posting a loss of $0.82 per share against a consensus estimate of $0.92, a beat of 10.85%, while revenue of $13.58 million edged ahead of the $13.41 million forecast by 1.22% and grew 2.2% year-over-year. The primary story behind the numbers, however, was the widening net loss to $78.22 million from $58.55 million a year ago, as R&D spending climbed to $83.02 million from $67.22 million to fund accelerating enrollment in the DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL. Data presented at ASH 2025 showed an 83% objective response rate in Phase 1a, lending clinical weight to that spending. The company ended the period with $592.90 million in cash after a $250.00 million equity offering, though investors have taken note of widening annual losses of $264.46 million and dilution concerns. Looking ahead, Nurix plans to initiate a global Phase 3 confirmatory trial comparing bexobrutideg to pirtobrutinib in the first half of 2026, with an autoimmune IND also targeted for the year.
- Revenue increase for full year driven by $30 million in Sanofi license extension revenue
- Research milestones of $7 million from Sanofi and $5 million from Pfizer during fiscal year 2025
- $5 million clinical milestone from Gilead collaboration
- Revenue partially offset by decrease as initial research terms for certain drug targets ended under Sanofi and Gilead collaborations
“The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreakâ„¢ registrational program for bexobrutideg and strengthened our balance sheet to support execution across our pipeline. With regulatory alignment on Phase 2 dose, compelling Phase 1 clinical data in CLL, and the continued advancement of our autoimmune and immuno-oncology programs, we believe we are well positioned to deliver the benefits of degrader-based medicines to significant populations of patients in need of new therapies.”
Nurix Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Nurix plans to continue enrollment in the DAYBreakâ„¢ pivotal Phase 2 single-arm study (CLL-201) of bexobrutideg in relapsed/refractory CLL designed to support a potential Accelerated Approval submission. The company plans to initiate a global randomized confirmatory Phase 3 trial (DAYBreak CLL-306) in the first half of 2026, comparing bexobrutideg to pirtobrutinib. A potential autoimmune disease IND for bexobrutideg is targeted for 2026, supported by ongoing Phase 1 healthy volunteer studies. The company expects to continue achieving research collaboration milestones with Gilead, Sanofi, and Pfizer throughout the terms of those collaborations. Nurix also plans to advance the STAT6 degrader NX-3911 through IND-enabling studies with Sanofi and to provide preclinical, clinical, and program updates at major medical conferences throughout 2026.
NRIX YoY Financials
NRIX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.